- $420.96m
- $132.77m
- $9.68m
Brief: Prothena To Review Birtamimab Mechanism Of Action, Pharmacological Characteristics Published In Leukemia & Lymphoma
Prothena Corporation PLC reports results for the quarter ended in December - Earnings Summary
Brief: Prothena Q4 Net Income USD -67.476 Million
Prothena Corporation PLC expected to post a loss of $1.22 a share - Earnings Preview
Prothena Corporation PLC expected to post a loss of $1.22 a share - Earnings Preview
Brief: Prothena Provides Updates On Portfolio Programs
Prothena falls on apprehensions around Alzheimer's drug update
Focus: Researchers return to Alzheimer's vaccines, buoyed by recent drug success
Prothena Corporation PLC reports results for the quarter ended in September - Earnings Summary
Brief: Prothena Q3 Net Income USD 21.907 Million
Prothena Corporation PLC expected to post a loss of 32 cents a share - Earnings Preview
Prothena Corporation PLC expected to post a loss of 32 cents a share - Earnings Preview
Prothena jumps on report of biotech firm exploring potential sale
Prothena prepares for potential sale - Bloomberg News (updated)
Prothena preparing for a potential sale - Bloomberg News
Media: Biotech firm Prothena prepares for potential sale - Bloomberg News
Prothena Corporation PLC reports results for the quarter ended in June - Earnings Summary
Brief: Prothena Q2 Net Income USD -54.595 Million
Prothena Corporation PLC expected to post a loss of 100 cents a share - Earnings Preview